Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Mouth, Edentulous D009066 1 associated lipids
Pelvic Pain D017699 7 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Capillary Leak Syndrome D019559 2 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Migraine without Aura D020326 1 associated lipids
Peanut Hypersensitivity D021183 2 associated lipids
Egg Hypersensitivity D021181 1 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Pneumonia, Pneumococcal D011018 3 associated lipids
Dictyocaulus Infections D004022 1 associated lipids
Bovine Virus Diarrhea-Mucosal Disease D001912 2 associated lipids
Jaundice, Obstructive D041781 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Leukostasis D018921 1 associated lipids
Pulmonary Atelectasis D001261 1 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Lee T et al. Increased biosynthesis of platelet-activating factor in activated human eosinophils. 1984 J. Biol. Chem. pmid:6425292
Hallam TJ et al. Stimulus-response coupling in human platelets. Changes evoked by platelet-activating factor in cytoplasmic free calcium monitored with the fluorescent calcium indicator quin2. 1984 Biochem. J. pmid:6426464
Hillmar I et al. Effects of a thio analog of platelet-activating factor on platelet aggregation and adenosine 3',5'-monophosphate concentration in hepatocyte suspensions and in platelets. A comparison with the naturally occurring compound. 1984 Hoppe-Seyler's Z. Physiol. Chem. pmid:6325321
Valone FH Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-2-acetyl-SN-glycero-3-phosphorylcholine. 1984 Immunology pmid:6325330
Kramp W et al. Observations on the critical micellar concentration of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and a series of its homologs and analogs. 1984 Chem. Phys. Lipids pmid:6744496
Smith RJ et al. Effects of an anion channel blocker, 4, 4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS), on human neutrophil function. 1984 Biochem. Biophys. Res. Commun. pmid:6329191
Lefort J et al. The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene. 1984 Br. J. Pharmacol. pmid:6430375
Hamasaki Y et al. Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. 1984 Am. Rev. Respir. Dis. pmid:6547031
Pirotzky E et al. Release of platelet-activating factor, slow-reacting substance, and vasoactive amines from isolated rat kidneys. 1984 Kidney Int. pmid:6144811
Gómez-Cambronero J et al. The role of calcium ions in the process of acetyltransferase activation during the formation of platelet-activating factor (PAF-acether). 1984 Biochem. J. pmid:6146309
Morley J et al. The platelet in asthma. 1984 Lancet pmid:6150192
Kloprogge E and Akkerman JW Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets. 1984 Biochem. J. pmid:6150705
Hanahan DJ and Nelson DR Phospholipids as dynamic participants in biological processes. 1984 J. Lipid Res. pmid:6152281
Dahlbäck M et al. Bronchial anaphylaxis in actively sensitized Sprague Dawley rats: studies on mediators involved. 1984 Acta Pharmacol Toxicol (Copenh) pmid:6431753
Rao AK et al. Platelet-activating factor is a weak platelet agonist: evidence from normal human platelets and platelets with congenital secretion defects. 1984 Am. J. Hematol. pmid:6431801
Clay KL et al. Structure elucidation of platelet activating factor derived from human neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6430285
Siess W et al. Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-activating factor. Epinephrine does not induce phospholipase C activation or platelet shape change. 1984 J. Biol. Chem. pmid:6429141
Nishihira J et al. Production and characterization of specific antibodies against 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a potent hypotensive and platelet-activating ether-linked phospholipid). 1984 J. Biochem. pmid:6430883
Malpass TW et al. The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. 1984 J. Thorac. Cardiovasc. Surg. pmid:6231433
Willoughby WF and Willoughby JB Immunologic mechanisms of parenchymal lung injury. 1984 Environ. Health Perspect. pmid:6234162
Goldstein BM et al. Effect of platelet activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat. 1984 Life Sci. pmid:6482659
Baldo BA and Tovey ER Allergy, allergens and allergen standardization. 1984 Med. J. Aust. pmid:6482786
Saeki S et al. Effect of 1-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine on blood pressure by intra-lateral ventricular injection in the rat. 1984 Med J Osaka Univ pmid:6482814
Nishizawa EE and Della-Coletta AA The formation of a thrombin-like material (TLM) following stimulation of leukocytes. 1984 Thromb. Res. pmid:6484896
Satouchi K et al. Metabolism of 1-O-alkyl-2-acetyl-sn-glycerol by washed rabbit platelets: formation of platelet activating factor. 1984 Arch. Biochem. Biophys. pmid:6486825
Nakamura N et al. Synthesis and biological activities of bioisosteric O-carba-analogues of platelet activating factor (PAF). 1984 Chem. Pharm. Bull. pmid:6488414
Page CP et al. Platelets and bronchospasm. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6735490
Jouvin-Marche E et al. Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. 1984 J. Immunol. pmid:6736649
Renal syndromes and nonsteroidal antiinflammatory drugs. 1984 N. Engl. J. Med. pmid:6738607
Hoffman DR et al. Cytotoxicity of ether-linked phytanyl phospholipid analogs and related derivatives in human HL-60 leukemia cells and polymorphonuclear neutrophils. 1984 Res. Commun. Chem. Pathol. Pharmacol. pmid:6739956
Mohanty D and Hilgard P A new platelet aggregating material (PAM) in an experimentally induced rat fibrosarcoma. 1984 Thromb. Haemost. pmid:6740552
Blank ML et al. A new class of antihypertensive neutral lipid: 1-alkyl-2-acetyl-sn-glycerols, a precursor of platelet activating factor. 1984 Biochem. Biophys. Res. Commun. pmid:6696762
Williams KA and Haslam RJ Effects of NaCl and GTP on the inhibition of platelet adenylate cyclase by 1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (synthetic platelet-activating factor). 1984 Biochim. Biophys. Acta pmid:6696908
Hoffman DR et al. Cytotoxicity of platelet activating factor and related alkyl-phospholipid analogs in human leukemia cells, polymorphonuclear neutrophils, and skin fibroblasts. 1984 Blood pmid:6696992
Archer CB et al. Inflammatory characteristics of platelet activating factor (PAF-acether) in human skin. 1984 Br. J. Dermatol. pmid:6581831
Andreesen R et al. Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. 1984 J. Natl. Cancer Inst. pmid:6582303
Prescott SM et al. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. 1984 Proc. Natl. Acad. Sci. U.S.A. pmid:6587368
O'Neill C and Saunders DM Assessment of embryo quality. 1984 Lancet pmid:6149413
Billah MM and Siegel MI Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6422930
Prevost MC et al. Platelet activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxia. 1984 Biochem. Biophys. Res. Commun. pmid:6422938
Mojarad M et al. Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. A preliminary report. 1983 May-Jun Bull Eur Physiopathol Respir pmid:6882949
Pazzi A et al. [Platelet activation in vivo. Electron microscopy study of a case of type II diabetes]. 1983 Mar-Apr G Clin Med pmid:6884636
Hillmar I and Zöllner N Saturated and unsaturated 1-0-alkyl-2-0-acetoyl-sn-glycero-3-phosphocholines and 2-lyso derivatives from ratfish liver oil. Effect on adenosine 3':5'-cyclic monophosphate concentration in hepatocyte suspensions. 1983 Res Exp Med (Berl) pmid:6310713
Mauco G et al. Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets. 1983 FEBS Lett. pmid:6311620
Camussi G et al. Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. 1983 J. Immunol. pmid:6311899
Hwang SB et al. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. 1983 Biochemistry pmid:6313047
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Mencia-Huerta JM et al. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. 1983 J. Immunol. pmid:6315819
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Voelkel NF et al. Platelet-activating factor causes pulmonary vasoconstriction and edema via platelet-independent leukotriene formation. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221590
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Swendsen CL et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. 1983 Biochem. Biophys. Res. Commun. pmid:6407484
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Heffner JE et al. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. 1983 J. Clin. Invest. pmid:6822668
Keraly CL et al. Effect of structural analogues of PAF-acether on platelet desensitization. 1983 Br. J. Haematol. pmid:6824590
Tence M et al. The enantiomer and the positional isomer of platelet-activating factor. 1983 Biochim. Biophys. Acta pmid:6824744
Camussi G et al. Biosynthesis and release of platelet-activating factor from human monocytes. 1983 Int. Arch. Allergy Appl. Immunol. pmid:6826235
Randolph AE et al. Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats. 1983 Clin Exp Hypertens A pmid:6684006
Morley J et al. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. 1983 Br. J. Pharmacol. pmid:6685552
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Garcia Gil M and Sanchez Crespo M Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. 1983 Immunopharmacology pmid:6654649
McDonald TP and Kalmaz GD Effects of thrombopoietin on the number and diameter of marrow megakaryocytes of mice. 1983 Exp. Hematol. pmid:6832243
Lewis JC et al. Platelet-activating factor effects on pulmonary ultrastructure in rabbits. 1983 Exp. Mol. Pathol. pmid:6832335
Levy JV Calmodulin antagonists inhibit aggregation of human, guniea pig and rabbit platelets induced with platelet activating factor. 1983 FEBS Lett. pmid:6832368
Touqui L et al. Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite. 1983 Biochem. Biophys. Res. Commun. pmid:6838557
Billah MM and Johnston JM Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. 1983 Biochem. Biophys. Res. Commun. pmid:6407483
Worthen GS et al. Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. 1983 Chest pmid:6839840
Heffner JE et al. Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. 1983 Chest pmid:6839854
Levy JV Calmodulin antagonist W-7 inhibits aggregation of human platelets induced by platelet activating factor. 1983 Proc. Soc. Exp. Biol. Med. pmid:6844347
O'Flaherty JT et al. Platelet-activating factor and analogues: comparative studies with human neutrophils and rabbit platelets. 1983 Res. Commun. Chem. Pathol. Pharmacol. pmid:6844746
Valone FH and Goetzl EJ Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. 1983 Immunology pmid:6848449
Chilton FH et al. Metabolic fate of platelet-activating factor in neutrophils. 1983 J. Biol. Chem. pmid:6853486
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Hartung HP et al. Platelet activating factor (PAF) induces the oxidative burst in macrophages. 1983 Int. J. Immunopharmacol. pmid:6874164
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
1st International Symposium on Platelet-Activating Factor (PAF-ACETHER, AGEPC) and structurally related ether-lipids. Paris (France) June 26-29, 1983. Abstracts. 1983 J Pharmacol pmid:6876807
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Cargill DI et al. Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). 1983 Thromb. Haemost. pmid:6879508
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Virella G et al. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. 1983 Immunology pmid:6885111
Camussi G et al. Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. 1983 Immunopharmacology pmid:6885382
Vermylen J et al. Normal mechanisms of platelet function. 1983 Clin Haematol pmid:6301715
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519